» Articles » PMID: 36457074

Risk Stratification of Lateral Neck Recurrence for Patients with PN1a Papillary Thyroid Cancer

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2022 Dec 2
PMID 36457074
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lateral neck is not recommended for dissection in patients with pN1a papillary thyroid cancer (PTC), but its recurrence risk has not been well stratified. We aimed to develop a risk stratification system for lateral neck recurrence in patients with pN1a PTC.

Methods: Patients with pN1a PTC who underwent thyroidectomy and unilateral central compartment dissection from 2000-2016 were enrolled. The association between number of central lymph node metastases (CLNMs) and lateral neck recurrence was comprehensively assessed using a Cox proportional hazards model with restricted cubic spline. Stratification was then performed based on CLNMs and other significant risk factors selected by multivariate analysis. Lateral neck recurrent-free survival (LRFS) rate of each stratification was estimated with Kaplan-Meier curve and comparison was performed using log-rank test.

Results: Ninety-six (3.8%) lateral neck recurrences were identified during a median follow-up of 62 months among a total of 2500 admitted cases. An increasing number of CLNMs was associated with compromised LRFS for up to 6 CLNMs (P < 0.001), and CLNMs > 3 indicated significantly worse 5-year LRFS than that of CLNM ≤ 3 (90.6% vs. 98.1%, P < 0.001). When stratification with CLNMs and primary tumor size (selected by multivariate analysis, HR (95%CI) = 4.225(2.460-7.256), P < 0.001), 5-year LRFS rates of high- (CLNMs > 3 and primary tumor size > 2 cm), intermediate- (CLNMs > 3 and primary tumor size 1-2 cm) and low-risk (primary tumor size ≤ 1 cm or CLNMs ≤ 3) groups were 78.5%, 90.0% and 97.9%, respectively (P < 0.05).

Conclusions: The number of CLNMs combined with primary tumor size seems to effectively stratify lateral neck recurrence risk for patients with pN1a PTC.

Citing Articles

Risk factors and distribution pattern of lateral lymph node recurrence after central neck dissection for cN1a papillary thyroid carcinoma.

Long B, Luo M, Zhou K, Zheng T, Li W BMC Surg. 2024; 24(1):270.

PMID: 39334088 PMC: 11428479. DOI: 10.1186/s12893-024-02564-3.


Prediction of lateral neck metastasis in patients with papillary thyroid cancer with suspicious lateral lymph ultrasonic imaging based on central lymph node metastasis features.

Xu Y, Zhang C Oncol Lett. 2024; 28(4):472.

PMID: 39211301 PMC: 11358722. DOI: 10.3892/ol.2024.14605.


Risk factors for cervical lymph node metastasis of papillary thyroid cancer in elderly patients aged 65 and older.

Zhang Y, Ji X, Yang Z, Wang Y Front Endocrinol (Lausanne). 2024; 15:1418767.

PMID: 38978619 PMC: 11228152. DOI: 10.3389/fendo.2024.1418767.


A nomogram for predicting lateral lymph node metastasis in cN0 unifocal papillary thyroid microcarcinoma.

Huang H, Xu S, Ni S, Wang X, Liu S BMC Cancer. 2023; 23(1):718.

PMID: 37528388 PMC: 10391989. DOI: 10.1186/s12885-023-11219-0.

References
1.
Schlumberger M, Leboulleux S . Current practice in patients with differentiated thyroid cancer. Nat Rev Endocrinol. 2020; 17(3):176-188. DOI: 10.1038/s41574-020-00448-z. View

2.
Randolph G, Duh Q, Heller K, LiVolsi V, Mandel S, Steward D . The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012; 22(11):1144-52. DOI: 10.1089/thy.2012.0043. View

3.
Lim Y, Liu L, Chang J, Koo B . Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis. Oral Oncol. 2016; 62:109-113. DOI: 10.1016/j.oraloncology.2016.10.010. View

4.
Udelsman R, Chen H . The current management of thyroid cancer. Adv Surg. 1999; 33:1-27. View

5.
Wang L, Migliacci J, Tuttle R, Shaha A, Shah J, Patel S . Management and outcome of clinically evident neck recurrence in patients with papillary thyroid cancer. Clin Endocrinol (Oxf). 2017; 87(5):566-571. PMC: 5658234. DOI: 10.1111/cen.13378. View